BRETEC — Bioretec Oy Share News
0.000.00%
Last trade - 00:00- €28.71m
- €16.69m
- €3.52m
Brief: Bioretec Has Submitted Additional Information Requested By The FDA For US Registration Of Remeos Trauma Screws
Brief: Bioretec Expects European Marketing Authorization For Remeos Trauma Screw To Be Delayed From Original Estimate Of 2022
Brief: Bioretec Expects FDA Approval For RemeOs Screws In April 2023
Brief: Bioretec's Hybrid Composite Patent Approved In Europe
Brief: Bioretec H1 Net Loss Narrows To EUR 1.4 Mln
Brief: Bioretec Enters Into 5-Year Exclusive Distribution Agreement
Brief: Bioretec Submits De Novo Request For Market Authorization In U.S.
Brief: Bioretec H2 Net Loss Widens To EUR 3.2 Mln
Brief: Bioretec Enters Into Supply Agreement With Meotec